Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Summary

Takeda announced positive topline results from a pivotal Phase 2/3 clinical trial of TAK-881 in primary immunodeficiency disease (PID). The positive outcome represents meaningful clinical progress for the investigational treatment.